These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 24255756)

  • 1. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia.
    Putra IB; Hamid AR; Mochtar CA; Umbas R
    Prostate Int; 2016 Jun; 4(2):43-8. PubMed ID: 27358842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review.
    Russo GI; Larganà G; Sebastianelli A; Cocci A; Mauro MD; Rapallo I; Morgia G; Morgia MM; La Vignera S; Condorelli R; Calogero AE; Olivotto I; Morselli S; Serni S; Gacci M
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33499215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome and benign prostatic hyperplasia: An update.
    Ngai HY; Yuen KS; Ng CM; Cheng CH; Chu SP
    Asian J Urol; 2017 Jul; 4(3):164-173. PubMed ID: 29264226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 27-Hydroxycholesterol stimulates cell proliferation and resistance to docetaxel-induced apoptosis in prostate epithelial cells.
    Raza S; Meyer M; Schommer J; Hammer KD; Guo B; Ghribi O
    Med Oncol; 2016 Feb; 33(2):12. PubMed ID: 26732475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result.
    Shi Y; Fung KZ; Freedland SJ; Hoffman RM; Tang VL; Walter LC
    Urology; 2014 Nov; 84(5):1058-65. PubMed ID: 25443902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.
    Emberton M; Cornel EB; Bassi PF; Fourcade RO; Gómez JM; Castro R
    Int J Clin Pract; 2008 Jul; 62(7):1076-86. PubMed ID: 18479366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of treatment with statins on prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia.
    Lee SH; Park TJ; Bae MH; Choi SH; Cho YS; Joo KJ; Kwon CH; Park HJ
    Korean J Urol; 2013 Nov; 54(11):750-5. PubMed ID: 24255756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Allott EH; Csizmadi I; Howard LE; Muller RL; Moreira DM; Andriole GL; Roehrborn CG; Freedland SJ
    BJU Int; 2020 Feb; 125(2):226-233. PubMed ID: 31479563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin pretreatment and presentation patterns in patients with coronary artery disease.
    Ndrepepa G; Fusaro M; King L; Cassese S; Tada T; Schömig A; Kastrati A
    Cardiol J; 2013; 20(1):52-8. PubMed ID: 23558811
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.